Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-further-important-pre-clinical-milestone-in-endometriosis-alliance-with-bayer-5396
Evotec enters into strategic multi-target alliance with C4X Discovery
Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc („C4XD“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-strategic-multi-target-alliance-with-c4x-discovery-5394
Evotec enters into a research collaboration with Inserm in oncology
Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research („Inserm“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-a-research-collaboration-with-inserm-in-oncology-5392
Evotec and Bayer partner to develop new treatments to fight kidney diseases
Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-partner-to-develop-new-treatments-to-fight-kidney-diseases-5387
Evotec AG reports results of first half of 2016
Evotec AG today reported financial results and corporate updates for the first half of 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-half-of-2016-5384
Evotec achieves clinical development milestone as part of its multi-target alliance with Bayer in endometriosis
Evotec AG announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-clinical-development-milestone-as-part-of-its-multi-target-alliance-with-bayer-in-endometriosis-5382
Ad hoc: Evotec AG increases its profitability guidance for 2016
Evotec AG today announced that, in the context of the half year results published on 10 August 2016, it increases its financial guidance for the current year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-increases-its-profitability-guidance-for-2016-5378
Evotec awarded contract from Antibiotic Research UK to begin integrated drug discovery collaboration
Evotec AG announced today a collaboration with Antibiotic Research UK („ANTRUK“) to identify alternative means of treating infections that are resistant to currently available antibiotics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-contract-from-antibiotic-research-uk-to-begin-integrated-drug-discovery-collaboration-5376
Evotec enters license agreement for access to CRISPR-Cas9 gene editing technology
Evotec AG announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-license-agreement-for-access-to-crispr-cas9-gene-editing-technology-5374
Evotec and Ellersbrook join forces to accelerate TargetNASH
Evotec AG announced today that the investment company Ellersbrook GmbH & Co. KG, („Ellersbrook“), Germany, will invest into Evotec’s internal TargetNASH programme. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ellersbrook-join-forces-to-accelerate-targetnash-5372